PCAS

Regulatory Filings • Jul 27, 2017

END OF THE LIQUIDITY CONTRACT BETWEEN PCAS AND KEPLER CHEUVREUX

Longjumeau, July 27, 2017

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the end of its liquidity contract with Kepler Cheuvreux.

The liquidity contract PCAS awarded to Kepler Cheuvreux was terminated on July 27, 2017.

When the contract was signed, the following assets were allocated to the liquidity account:

• securities: 18,893 PCAS shares
• cash: 116,565.86 euros.

On termination of the contract, the following assets were on the liquidity account:

• securities: 834 PCAS shares
• cash: 248,609.44 euros.

NEXT FINANCIAL DISCLOSURE:

First half 2017 earnings report, September 6, 2017

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €192.0 million in 2016 and employs close to 1000 people in six countries.

To find out more about PCAS, visit: www.pcas.com

Vincent Touraille / Eric Moissenot PCAS

Tel. : +33 1 69 79 61 32 www.pcas.com

PCAS NewCap

Emmanuel Huynh / Louis-Victor Delouvrier NewCap Financial communication and Investor Relations

Tel. : +33 1 44 71 98 53 pcas@newcap.eu